Nuclear Medicine and Biology
Volume 33, Issue 5 , Pages 607-614 , July 2006

Comparison of [18F]FDOPA, [18F]FMT and [18F]FECNT for imaging dopaminergic neurotransmission in mice

  • Michael Honer

      Affiliations

    • Center for Radiopharmaceutical Science of ETH, PSI and USZ, CH-8093 Zurich, Switzerland
    • Corresponding Author InformationCorresponding author. Animal Imaging Center–PET, Center for Radiopharmaceutical Sciences of ETH, PSI and USZ, ETH Hoenggerberg, CH-8093 Zurich, Switzerland. Tel.: +41 44 633 6084; fax: +41 44 633 1367.
    • ,
  • Bastian Hengerer

      Affiliations

    • Boehringer Ingelheim CNS Research II, D-88397 Biberach, Germany
    • ,
  • Milen Blagoev

      Affiliations

    • Center for Radiopharmaceutical Science of ETH, PSI and USZ, CH-8093 Zurich, Switzerland
    • ,
  • Samuel Hintermann

      Affiliations

    • Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland
    • ,
  • Peter Waldmeier

      Affiliations

    • Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland
    • ,
  • Pius A. Schubiger

      Affiliations

    • Center for Radiopharmaceutical Science of ETH, PSI and USZ, CH-8093 Zurich, Switzerland
    • ,
  • Simon M. Ametamey

      Affiliations

    • Center for Radiopharmaceutical Science of ETH, PSI and USZ, CH-8093 Zurich, Switzerland

Received 19 October 2005 ,Revised 3 April 2006 ,Accepted 11 April 2006.

References 

  1. Chatziioannou AF. Molecular imaging of small animals with dedicated PET tomographs. Eur J Nucl Med. 2002;29(1):98–114
  2. Schafers KP. Imaging small animals with positron emission tomography. Nuklearmedizin. 2003;42(3):86–89
  3. Brownell AL, Canales K, Chen YI, Jenkins BG, Owen C, Livni E, et al. Mapping of brain function after MPTP-induced neurotoxicity in a primate Parkinson's disease model. Neuroimage. 2003;20(2):1064–1075
  4. Brownell AL, Jenkins BG, Elmaleh DR, Deacon TW, Spealman RD, Isacson O. Combined PET/MRS brain studies show dynamic and long-term physiological changes in a primate model of Parkinson disease. Nat Med. 1998;4(11):1308–1312
  5. Cicchetti F, Brownell AL, Williams K, Chen YI, Livni E, Isacson O. Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. Eur J Neurosci. 2002;15(6):991–998
  6. Hume SP, Lammertsma AA, Myers R, Rajeswaran S, Bloomfield PM, Ashworth S, et al. The potential of high-resolution positron emission tomography to monitor striatal dopaminergic function in rat models of disease. J Neurosci Methods. 1996;67(2):103–112
  7. Nikolaus S, Larisch R, Beu M, Forutan F, Vosberg H, Muller Gartner H. Bilateral increase in striatal dopamine D2 receptor density in the 6-hydroxydopamine-lesioned rat: a serial in vivo investigation with small animal PET. Eur J Nucl Med Mol Imaging. 2003;30(3):390–395
  8. Takamatsu H, Kakiuchi T, Noda A, Uchida H, Nishiyama S, Ichise R, et al. An application of a new planar positron imaging system (PPIS) in a small animal: MPTP-induced parkinsonism in mouse. Ann Nucl Med. 2004;18(5):427–431
  9. Doudet DJ, McLellan CA, Carson R, Adams HR, Miyake H, Aigner TG, et al. Distribution and kinetics of 3-O-methyl-6-[18F]fluoro-l-dopa in the rhesus monkey brain. J Cereb Blood Flow Metab. 1991;11(5):726–734
  10. Firnau G, Sood S, Chirakal R, Nahmias C, Garnett ES. Metabolites of 6-[18F]fluoro-l-dopa in human blood. J Nucl Med. 1988;29(3):363–369
  11. Barrio JR, Huang SC, Yu DC, Melega WP, Quintana J, Cherry SR, et al. Radiofluorinated l-m-tyrosines: new in-vivo probes for central dopamine biochemistry. J Cereb Blood Flow Metab. 1996;16(4):667–678
  12. DeJesus OT, Endres CJ, Shelton SE, Nickles RJ, Holden JE. Evaluation of fluorinated m-tyrosine analogs as PET imaging agents of dopamine nerve terminals: comparison with 6-fluoroDOPA. J Nucl Med. 1997;38(4):630–636
  13. Brown WD, DeJesus OT, Pyzalski RW, Malischke L, Roberts AD, Shelton SE, et al. Localization of trapping of 6-[(18)F]fluoro-l-m-tyrosine, an aromatic l-amino acid decarboxylase tracer for PET. Synapse. 1999;34(2):111–123
  14. DeJesus OT, Endres CJ, Shelton SE, Nickles RJ, Holden JE. Noninvasive assessment of aromatic l-amino acid decarboxylase activity in aging rhesus monkey brain in vivo. Synapse. 2001;39(1):58–63
  15. Davis MR, Votaw JR, Bremner JD, Byas Smith MG, Faber TL, Voll RJ, et al. Initial human PET imaging studies with the dopamine transporter ligand 18F-FECNT. J Nucl Med. 2003;44(6):855–861
  16. Wong DF, Yung B, Dannals RF, Shaya EK, Ravert HT, Chen CA, et al. In vivo imaging of baboon and human dopamine transporters by positron emission tomography using [11C]WIN 35,428. Synapse. 1993;15(2):130–142
  17. Chaly T, Dhawan V, Kazumata K, Antonini A, Margouleff C, Dahl JR, et al. Radiosynthesis of [18F] N-3-fluoropropyl-2-beta-carbomethoxy-3-beta-(4-iodophenyl) nortropane and the first human study with positron emission tomography. Nucl Med Biol. 1996;23(8):999–1004
  18. VanBrocklin HF, Blagoev M, Hoepping A, O'Neil JP, Klose M, Schubiger PA, et al. A new precursor for the preparation of 6-[18F]fluoro-l-m-tyrosine ([18F]FMT): efficient synthesis and comparison of radiolabeling. Appl Radiat Isot. 2004;61(6):1289–1294
  19. Goodman MM, Kilts CD, Keil R, Shi B, Martarello L, Xing D, et al. 18F-labeled FECNT: a selective radioligand for PET imaging of brain dopamine transporters. Nucl Med Biol. 2000;27(1):1–12
  20. Pauwels T, Dethy S, Goldman S, Monclus M, Luxen A. Effect of catechol-O-methyl transferase inhibition on peripheral and central metabolism of 6-[F-18]fluoro-l-dopa. Eur J Pharmacol. 1994;257(1–2):53–58
  21. Jackson-Lewis V, Jakowec M, Burke RE, Przedborski S. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin. Neurodegeneration. 1995;4(3):257–269
  22. Schmidt N, Ferger B. Neurochemical findings in the MPTP model of Parkinson's disease. J Neural Transm. 2001;108(11):1263–1282
  23. Reader AJ, Erlandsson K, Flower MA, Ott RJ. Fast accurate iterative reconstruction for low-statistics positron volume imaging. Phys Med Biol. 1998;43(4):835–846
  24. Missimer J, Madi Z, Honer M, Keller C, Schubiger A, Ametamey SM. Performance evaluation of the 16-module quad-HIDAC small animal PET camera. Phys Med Biol. 2004;49(10):2069–2081
  25. Mikolajczyk K, Szabatin M, Rudnicki P, Grodzki M, Burger C. A JAVA environment for medical image data analysis: initial application for brain PET quantitation. Med Inform (Lond). 1998;23(3):207–214
  26. Myers R, Hume S, Bloomfield P, Jones T. Radio-imaging in small animals. J Psychopharmacol. 1999;13(4):352–357
  27. Cumming P, Ase A, Diksic M, Harrison J, Jolly D, Kuwabara H, et al. Metabolism and blood–brain clearance of l-3,4-dihydroxy-[3H]phenylalanine ([3H]DOPA) and 6-[18F]fluoro-l-DOPA in the rat. Biochem Pharmacol. 1995;50(7):943–946
  28. Melega WP, Grafton ST, Huang SC, Satyamurthy N, Phelps ME, Barrio JR. L-6-[18F]fluoro-dopa metabolism in monkeys and humans: biochemical parameters for the formulation of tracer kinetic models with positron emission tomography. J Cereb Blood Flow Metab. 1991;11(6):890–897
  29. DeJesus OT, Haaparanta M, Solin O, Nickles RJ. 6-fluoroDOPA metabolism in rat striatum: time course of extracellular metabolites. Brain Res. 2000;877(1):31–36
  30. Melega WP, Luxen A, Perlmutter MM, Nissenson CH, Phelps ME, Barrio JR. Comparative in vivo metabolism of 6-[18F]fluoro-l-dopa and [3H]l-dopa in rats. Biochem Pharmacol. 1990;39(12):1853–1860
  31. Wahl LM, Chen JJ, Thompson M, Chirakal R, Nahmias C. The time course of metabolites in human plasma after 6-[(18)F]fluoro-l-m-tyrosine administration. Eur J Nucl Med. 1999;26(11):1407–1412
  32. Honer M, Bruhlmeier M, Missimer J, Schubiger AP, Ametamey SM. Dynamic imaging of striatal D2 receptors in mice using quad-HIDAC PET. J Nucl Med. 2004;45(3):464–470
  33. Lundkvist C, Halldin C, Ginovart N, Swahn CG, Farde L. [18F] beta-CIT-FP is superior to [11C] beta-CIT-FP for quantitation of the dopamine transporter. Nucl Med Biol. 1997;24(7):621–627
  34. Goodman MM, Keil R, Shoup TM, Eshima D, Eshima L, Kilts C, et al. Fluorine-18-FPCT: a PET radiotracer for imaging dopamine transporters. J Nucl Med. 1997;38(1):119–126
  35. Jagoda EM, Vaquero JJ, Seidel J, Green MV, Eckelman WC. Experiment assessment of mass effects in the rat: implications for small animal PET imaging. Nucl Med Biol. 2004;31(6):771–779
  36. Kung MP, Kung HF. Mass effect of injected dose in small rodent imaging by SPECT and PET. Nucl Med Biol. 2005;32(7):673–678
  37. Votaw J, Byas Smith M, Hua J, Voll R, Martarello L, Levey AI, et al. Interaction of isoflurane with the dopamine transporter. Anesthesiology. 2003;98(2):404–411
  38. Elfving B, Bjornholm B, Knudsen GM. Interference of anaesthetics with radioligand binding in neuroreceptor studies. Eur J Nucl Med Mol Imaging. 2003;30(6):912–915

PII: S0969-8051(06)00071-0

doi: 10.1016/j.nucmedbio.2006.04.005

Nuclear Medicine and Biology
Volume 33, Issue 5 , Pages 607-614 , July 2006

Article Tools

* Image Usage & Resolution